Rhythm Pharmaceuticals, Inc. (RYTM) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
RYTM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RYTM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 89.7% | -101.2% | -103.6% |
| 2024 | 89.7% | -204.0% | -200.3% |
| 2023 | 88.0% | -238.1% | -238.5% |
| 2022 | 91.0% | -757.9% | -766.2% |
| 2021 | 81.0% | -5391.9% | -2207.1% |
Download Data
Export RYTM earnings history in CSV or JSON format
Free sign-in required to download data
Rhythm Pharmaceuticals, Inc. (RYTM) Earnings Overview
As of May 8, 2026, Rhythm Pharmaceuticals, Inc. (RYTM) reported trailing twelve-month net income of -$204M, reflecting +28.3% year-over-year growth. The company earned $-3.00 per diluted share over the past four quarters, with a net profit margin of -103.6%.
Looking at the long-term picture, RYTM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2014.
Rhythm Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($317M net income, 22.7% margin), RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), RYTM has room to improve margins relative to the peer group. Compare RYTM vs HALO →
RYTM Earnings vs Peers
Earnings metrics vs comparable public companies
RYTM Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$197M | +24.6% | -$192M | $-3.11 | -103.6% | -101.2% |
| 2024 | -$261M | -41.1% | -$266M | $-4.34 | -200.3% | -204.0% |
| 2023 | -$185M | -2.0% | -$184M | $-3.20 | -238.5% | -238.1% |
| 2022 | -$181M | -160.2% | -$179M | $-3.51 | -766.2% | -757.9% |
| 2021 | -$70M | +46.8% | -$170M | $-1.37 | -2207.1% | -5391.9% |
| 2020 | -$131M | +2.9% | -$137M | $-2.96 | - | - |
| 2019 | -$135M | -81.8% | -$146M | $-3.70 | - | - |
| 2018 | -$74M | -119.7% | -$78M | $-2.39 | - | - |
| 2017 | -$34M | -30.3% | -$32M | $-1.26 | - | - |
| 2016 | -$26M | -133.6% | -$26M | $-1.55 | - | - |
See RYTM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RYTM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RYTM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRYTM — Frequently Asked Questions
Quick answers to the most common questions about buying RYTM stock.
Is RYTM growing earnings?
RYTM EPS is $-3.00, with earnings growth accelerating to +28.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-204M.
What are RYTM's profit margins?
Rhythm Pharmaceuticals, Inc. net margin is -103.6%, with operating margin at -101.2%. Below-average margins reflect competitive or cost pressures.
How consistent are RYTM's earnings?
RYTM earnings data spans 2012-2025. The accelerating earnings trend is +28.3% YoY. Historical data enables comparison across business cycles.